Estimating the market size for a dual prevention pill: adding contraception to pre-exposure prophylaxis (PrEP) to increase uptake
|
31 July 2020
Research findings suggest that the dual prevention pill (DPP), an oral contraceptive combined with pre-exposure prophylaxis (PrEP) to prevent HIV in women, may lead to a 2- to 10-fold increase in PrEP use in 15 sub-Saharan countries -- a potential market of more than 1 million users. DPP consists of a 28-day dual prevention pill regimen in development by Population Council and currently in Phase 4 Post-marketing Trials. Begg L., Brodsky R., Friedland B. , Mathur, S., Sailer J., & Creasy G.
|
In this Journal Article:
Health Risk(s): HIV Unintended Pregnancy
Product Type(s): Contraceptives Hormonal Contraceptives MPTs
Topic(s):MPTs Product Development Product Introduction / Uptake Product Trials
Region(s): Africa Global
